BTIG lowered the firm’s price target on AtriCure (ATRC) to $52 from $58 and keeps a Buy rating on the shares. The company’s Q1 saw particularly strong sales from U.S. Appendage Management and the Cryosphere products in U.S. Pain Management, but much of this outperformance was offset by more pronounced weakness in the U.S. Minimally Invasive Ablation segment, as the Convergent procedure continued to face pressure from the distraction of pulsed field ablation adoption, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure price target lowered to $51 from $52 at Canaccord
- Atricure’s Strong Q1 2025 Performance and Conservative Guidance Justifies Buy Rating Despite Price Target Adjustment
- AtriCure, Inc. Reports Strong Q1 2025 Growth
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M
- AtriCure reports Q1 adjusted EPS (14c), consensus (22c)